Yes Migy119 - it will or might get way worst before they get better revenues.
This is the hard reality points:
- we are in a risk averse period,
- Biotechs are high risk segments to begin with,
- Revenue is key to any company, let alone OSX - they are below par at this stage, so they have a very low fair value
- They have low to no cash, further dilution is possible. Investors know this.
Until they show revenue growth, all their prospects are fluff talk. It might work out - but we have to wait for a few years and track them.
Ann: MOU with Temasek-linked Innoventures - Orthopaedics in China, page-30
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.002(5.00%) |
Mkt cap ! $4.390M | |||
| Open | High | Low | Value | Volume |
| 4.0¢ | 4.0¢ | 3.8¢ | $2.434K | 63.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 399387 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.0¢ | 1000000 | 1 |
View Market Depth
| Last trade - 14.13pm 07/10/2024 (20 minute delay) ? |
| OSX (ASX) Chart |